Nibec
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Nibec makes biomaterials used in dental procedures, products that help bone and tissue regenerate after implant surgery.
Its dental regeneration materials are distributed globally through major implant companies and carry regulatory approvals including the U.S. FDA, European CE marking, and China's NMPA. Listed on KOSDAQ, Korea's tech-focused small-cap exchange, the company's core business is dental tissue-regeneration materials, which it has expanded by developing peptide-fused medical devices and a new bone-graft product it describes as the first of their kind to reach commercialisation.
Summary is AI-generated and may contain errors · figures from DART filings
Post-market clinical studies for its collagen regeneration materials are running through Seoul National University Hospital in Korea and a university in Frankfurt, Germany.
Nibec in five facts
What does Nibec do?
Nibec makes biomaterials used in dental procedures, products that help bone and tissue regenerate after implant surgery.
Where is Nibec listed and in which sector?
Nibec (Korean name: 나이벡) trades under KRX code 138610 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Nibec?
Its market capitalisation was US$133.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Nibec's latest annual revenue and operating profit?
For fiscal year 2025, Nibec reported revenue of US$24.7M, operating profit of US$3.8M and net income of US$3.5M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 33.3% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Early redemption of convertible bonds (incl. overseas CBs)
Nibec Co., Ltd. redeemed US$28.6K face amount of its Series 8 convertible bonds (issued 2022-11-22, maturing 2027-11-22, conversion price US$15.34/share) before maturity at a put-option rate of 111.8602%, paying US$32K including premium on 2026-08-24; US$198K of the series remains outstanding and the acquired bonds will be retired.
Capital raise · Aug 24 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Nibec reported separate results for FY2025: revenue of US$22.7M (+33.3% year on year), operating profit of US$3.49M (from a loss a year earlier) and net income of US$3.21M (from a loss a year earlier).
Earnings · Feb 24